Login to Your Account



Financings Roundup

Conatus Pharma Seeks $69M for Liver Drug Emricasan

By Marie Powers
Staff Writer

Monday, June 17, 2013

Conatus Pharmaceuticals Inc., which has quietly labored on liver drug emricasan (IDN-6556) since gaining global rights to the asset in its 2010 acquisition of Pfizer Inc. spin-out Idun Pharmaceuticals Inc., became the latest biotech to register with the SEC for an initial public offering (IPO).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription